Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ASMB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nucleoside Reverse Transcriptase Inhibitor | Chronic Hepatitis B | Phase 2 · NCT04454567 | Terminated |
| Entecavir | Chronic Hepatitis B | Phase 2 · NCT04781647 | Terminated |
| AB-729 | Chronic Hepatitis B | Phase 2 · NCT04820686 | Terminated |
| Peg-IFNα | Chronic Hepatitis B | Phase 2 · NCT04781647 | Terminated |
| ABI-H2158 | Chronic Hepatitis B | Phase 2 · NCT04398134 | Terminated |
| Vebicorvir | Chronic Hepatitis B | Phase 2 · NCT04781647 | Terminated |
| ABI-6250 | Chronic Hepatitis D Infection | Phase 2 · NCT07762027 | Not yet recruiting |
| Esomeprazole | Chronic Hepatitis B | Phase 1 · NCT04142762 | Completed |
| Nucleos(t)ide | Chronic Hepatitis B | Phase 1 · NCT02908191 | Completed |
| Ethinyl Estradiol/Levonorgestrel | Chronic Hepatitis B | Phase 1 · NCT04142762 | Completed |
| ABI-M201 | Ulcerative Colitis Chronic Mild | Phase 1 · NCT03923478 | Terminated |
| ABI-H3733 Solid Oral Dosage Form | Chronic Hepatitis B | Phase 1 · NCT04271592 | Completed |
| ABI-H3733 Liquid Oral Dosage Form | Chronic Hepatitis B | Phase 1 · NCT04271592 | Completed |
| ABI-H3733 | Chronic Hepatitis B | Phase 1 · NCT05414981 | Completed |
| ABI-H2158 Test Formulation | Chronic Hepatitis B | Phase 1 · NCT04083716 | Completed |
| ABI-H2158 Reference Formulation | Chronic Hepatitis B | Phase 1 · NCT04083716 | Completed |
Also used in these trials (approved or third-party drugs, not ASMB's own candidates): Peginterferon Alfa-2A, Tenofovir Disoproxil Fumarate, Rifampin, Midazolam Hydrochloride, Itraconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ASMB holds $314.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.3M/quarter from operations, an estimated runway of 57.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 30 · Moderate
Based on our current operating plan and including the $75.0 million collaboration extension payment we received from Gilead in November 2026, we believe we have sufficient funds to meet our operating requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASMB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. 10% owner · +2.30M options |
Insider | 4,977,089 | 24.44% | 2026-05-26 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 1,604,590 | 7.88% | 2026-06-30 |
| Paradigm BioCapital Advisors LP | 5%+ holder (13G) | 1,553,748 | 7.63% | 2026-06-30 |
| Dapice Joshua J. | 5%+ holder (13G) | 1,227,590 | 6.03% | 2025-12-31 |
| Alexander Schornstein 10% owner |
Insider | 728,113 | 3.58% | 2024-11-22 |
| Jason A Okazaki CEO and President, Director · +71,100 options |
Insider | 195,532 | 0.96% | 2026-10-30 |
| William E IV Delaney Chief Scientific Officer · +25,500 options |
Insider | 74,035 | 0.36% | 2026-10-30 |
| Nicole S White Chief Manufacturing Officer · +20,400 options |
Insider | 59,257 | 0.29% | 2026-10-30 |
| Anuj Gaggar Chief Medical Officer · +24,200 options |
Insider | 53,800 | 0.26% | 2026-10-30 |
| John G McHutchison Director · +11,500 options |
Insider | 18,347 | 0.09% | 2025-03-31 |
| Jeanette M Bjorkquist PFO and PAO · +2,500 options |
Insider | 17,673 | 0.09% | 2026-10-30 |
| Michael Houghton Director · +11,500 options |
Insider | 3,202 | 0.02% | 2024-12-30 |
Share count 20,360,596 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASMB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →